Completed PHASE2 INTERVENTIONAL 1-arm NCT00378911

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus

Sponsor: Gynecologic Oncology Group

Conditions Recurrent Uterine Sarcoma Uterine Leiomyosarcoma

Interventions sunitinib malate

Updated 7 times since 2017 Last updated: Jul 22, 2019 Started: Oct 31, 2006 Primary completion: Jun 30, 2007 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00378911, this PHASE2 trial focuses on Recurrent Uterine Sarcoma and Uterine Leiomyosarcoma and remains completed. Sponsored by Gynecologic Oncology Group, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Aug 2019 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gynecologic Oncology Group
National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States